Clinical Trials
6 trialsNCT01314105 2025-02-13
BIBF 1120 + Carboplatin/Pegylated Liposomal Doxorubicin (PLD) in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT01583322 2023-09-06
CHIVA
ARCAGY/ GINECO GROUP
Phase 2 Completed
NCT01610869 2019-05-29
METRO-BIBF
University College, London
Phase 2 Completed
NCT01669798 2018-10-16
BIBF 1120 in Bevacizumab Resistant, Persistent, or Recurrent Epithelial Ovarian Cancer
Duke University
Phase 2 Completed
NCT01015118 2017-12-07
LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer
Boehringer Ingelheim
Phase 3 Completed
NCT00710762 2016-08-15
A Randomised Placebo-Controlled Phase II Study of Continuous Maintenance Treatment With BIBF 1120 Following Chemotherapy in Patients With Relapsed Ovarian Cancer
Boehringer Ingelheim
Phase 2 Completed